2137 — Brii Biosciences Balance Sheet
0.000.00%
Last trade - 00:00- HK$1.01bn
- -HK$1.91bn
- CNY0.62m
Annual balance sheet for Brii Biosciences, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 880 | 1,055 | 3,355 | 2,997 | 2,661 |
| Net Total Receivables | — | — | 51.5 | 57.7 | 71.1 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 885 | 1,093 | 3,414 | 3,077 | 2,783 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 56.8 | 43.9 | 33.4 | 19.5 | 5.61 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,039 | 1,268 | 3,612 | 3,392 | 3,198 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 61.9 | 575 | 281 | 229 | 126 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1,652 | 3,006 | 269 | 197 | 79.2 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | -613 | -1,738 | 3,343 | 3,195 | 3,119 |
| Total Liabilities & Shareholders' Equity | 1,039 | 1,268 | 3,612 | 3,392 | 3,198 |
| Total Common Shares Outstanding |